tapimmune presentation
DESCRIPTION
Presentation for Investors and those looking to be educated on our company.TRANSCRIPT
![Page 1: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/1.jpg)
04/12/2023 TapImmune IncOTC BB:TPIV
www.tapimmune.comOTCBB: TPIV
![Page 2: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/2.jpg)
04/12/2023 TapImmune Inc
Cautionary Statement Regarding Forward Looking Statements
Certain statements contained herein are forward-looking statements
within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this document include, but are not limited to, statements relating to long-term stability, the Company’s plan of operations and finances, the potential for the Company’s vaccines and proposed clinical trials. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and that actual results may differ materially from estimates in the forward-looking statements. The Company undertakes no obligation to revise these forward-looking statements to reflect events or circumstances after the date hereof.
![Page 3: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/3.jpg)
04/12/2023 TapImmune Inc
“ Development of Immunotherapies for cancer & infectious disease”
![Page 4: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/4.jpg)
04/12/2023 TapImmune Inc
Market for Immunotherapies/Vaccines
• Fastest growing segment of pharmaceutical market:– Cancer:
• Projected $6 billion U.S. for cancer vaccines by 2010 with CAGR of 70-100%
• Stimulated by recent approvals of Dendreon’s Provenge and BMS Yervoy
– Infectious Disease:• Projected market for 2010 - $11 billion• Viral pandemics, societal pathogens, bio-defense
![Page 5: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/5.jpg)
04/12/2023 TapImmune Inc
TAP Technology Platform
• TAP – Transporters associated with antigen presentation• Key component in immune recognition pathway• Stimulates T-cell recognition of antigens and production
of cytotoxic T-cells that can infiltrate tumors• Patents confer broad IP protection
![Page 6: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/6.jpg)
04/12/2023 TapImmune Inc
TAP is “switched off” in Cancer
• Many tumors have low or no expression of TAP• Tumors not recognized as foreign by immune system• Diminished expression of TAP is associated with disease
susceptibility, progression and metastasis • Vectors re-introducing TAP into tumors boost immunity
and reduce tumor burden
![Page 7: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/7.jpg)
04/12/2023 TapImmune Inc
Need to Augment TAP levels in Infectious Disease
• Viral infections produce a range of viral peptides that may “overwhelm” TAP system
• Insufficient viral antigens presented to the cellular immune system
• Diminished expression of TAP is associated with disease susceptibility
• Vectors augmenting normal TAP levels boost immunity and greatly improved vaccine efficacy
![Page 8: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/8.jpg)
04/12/2023 TapImmune Inc
Role of TAP (TAP1/TAP2) in loading peptides to MHC Class I molecules and presentation to Cytotoxic T-cells
![Page 9: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/9.jpg)
04/12/2023 TapImmune Inc
TAP treatment restores Immune Recognition in Cancer
Tumor cells now visible to the immune system
TAP
![Page 10: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/10.jpg)
04/12/2023 TapImmune Inc
TAP Enhances Immune Recognition inInfectious Disease
Greater number of viral antigens visible to the immune system
TAP
![Page 11: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/11.jpg)
04/12/2023 TapImmune Inc
Efficacy of TAP vector technology
• Cancer:– Mouse models of metastatic melanoma and
small cell lung cancer:• Reduced metastasis• Higher survival
• Infectious Disease:– 100-1000 fold increase in efficacy of smallpox
vaccine in animals.
![Page 12: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/12.jpg)
04/12/2023 TapImmune Inc
Clinical Development:HER2/neu +ve Breast Cancer Vaccine
• Combination of TAP + HER2/neu antigens from Mayo Clinic– applicable to ~ 80% of HER2/neu +ve patients– IND for Phase I studies approved
• Current therapy: – Trastuzumab (Herceptin) over $5billion in annual sales– applicable to ~ 30% of HER2/neu +ve patients
![Page 13: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/13.jpg)
04/12/2023 TapImmune Inc
ResearchSmallpox/Biodefense Vaccines
• TAP improved potency of smallpox vaccine by 100-1000 fold
• TAP + peptide antigens licensed from Mayo Clinic– Broader patient population; cheaper, longer shelf-life
• “Animal Efficacy Rule” FDA pathway (24-36 months to potential stockpiling)
• Potential for TAP to be stockpiled for variety of emerging bio-threats, e.g. Dengue
![Page 14: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/14.jpg)
04/12/2023 TapImmune Inc
Leverage of Collaborations
• Crucell NV– TAP manufacturing
• Research Collaboration with Aeras Global TB Vaccine Foundation – TB antigens (Phase II clinical) + TAP
• License Option Agreements with Mayo Clinic:– HER2/neu +ve breast cancer antigen technology– Smallpox virus antigen technology
![Page 15: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/15.jpg)
04/12/2023 TapImmune Inc
Advisors & R&D Team
– Mac Cheever (Corixa; Fred Hutchinson Cancer Center)
– Mark Reddish (Biomira; ID Biomedical)– Keith Knutson (Mayo Clinic)– Greg Poland (Mayo Clinic)– Lynn Depippo (Sherbrook Capital Management)
![Page 16: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/16.jpg)
04/12/2023 TapImmune Inc
• Technology discovery at University of British Columbia
• Founded as a public corporation on OTCBB (TPIV)
• Based in Seattle, WA
• ~ 47 million shares outstanding (22 million in float)
• Management & Affiliates ~ 30%
Corporate Profilewww.tapimmune.com
![Page 17: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/17.jpg)
04/12/2023 TapImmune Inc
Our Vision for TAP
• Leading immunotherapy in the fight against cancer:– Multiple metastatic cancers– Multiple combination products– Early stage prophylactic use
• Stockpiled for biodefense threats and viral pandemics:– Variety of infectious diseases– Emerging bio-terrorist threats– Making other vaccines more effective
![Page 18: TapImmune Presentation](https://reader036.vdocument.in/reader036/viewer/2022070317/55622f77d8b42af6668b54e5/html5/thumbnails/18.jpg)
04/12/2023 TapImmune Inc
Looking for Investors that Share our VisionWhy Invest in TPIV now?
• Breakthrough technology• Strong product pipeline• World-class team and collaborators• Risk diversification – cancer & infectious disease• Compelling preclinical data• Start of clinical programs• Undervalued and poised for significant growth